According to Anthony McDonnell, a senior policy analyst at the Center for Global Development, the Commission is right to promote the prudent use of antimicrobials. “However, market exclusivity vouchers are not the best way to do this,” he told EURACTIV, adding that a year of protected sales of the best-selling drugs in Europe would cost taxpayers and patients up to €5 billion. For him, much of this money will go to the company that buys the voucher, rather than the innovator that they want to encourage. "They will likely disrupt the generics market, and harm patients who need these expensive treatments,” he concluded.
